Houston AIDS Research Team (HART) CRS

Location	MSE R472, 6431 Fannin Street Houston, TX 77030 United States of America
CRS Coordinator	Maria Martinez maria.l.martinez@uth.tmc.edu 713-500-6718
CRS Leader	Roberto Arduino roberto.c.arduino@uth.tmc.edu 713-500-6731
Studies	A5128: US Genomic Sampling A5354: Early ART in Acute HIV A5359: The LATITUDE Study A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants A5332: REPRIEVE Trial A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5372: Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (RPT-DTG PK Study) A5371: A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B